查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1870668

依产品类型、最终用户、通路和给药途径分類的芽生菌病市场－2025-2032年全球预测

Blastomycosis Market by Product Type, End User, Distribution Channel, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，芽生菌病市场规模将成长至 2.1224 亿美元，复合年增长率为 3.43%。

关键市场统计数据
基准年 2024 1.6194亿美元
预计年份：2025年 1.6757亿美元
预测年份 2032 2.1224亿美元
复合年增长率 (%) 3.43%

芽生菌病的临床和商业性应用，重点在于诊断挑战、治疗路径和策略性相关人员的需求

芽生菌病仍是一种未被充分认识的真菌感染疾病，对临床路径、诊断流程设计和治疗策略有重大影响。儘管其发病率相对局限于地方性流行区，但由于症状特异性和现有检测方法的局限性，临床医生和医疗系统仍面临诊断延误的问题。因此，患者的预后取决于能否及时识别该疾病，以及能否获得可靠的诊断工具并配合有效的抗真菌治疗。从商业性角度来看，这种临床现实转化为对诊断创新、改进的分子检测和标靶治疗的明确需求驱动因素。

新的诊断创新、治疗方法的改进以及供应链的调整将重塑芽生菌病治疗方法的临床路径和市场机会。

在技​​术进步、监管重视和临床实践模式转变的推动下，芽生菌病领域正经历着一场变革性的转变。分子诊断领域的重大创新提高了检测的敏感度和速度，使得早期启动治疗成为可能。同时，血清学检测和影像判读框架的改进降低了诊断的不确定性，而诊断的不确定性历来是导致治疗延迟和预后不良的原因。这些诊断技术的进步正在重塑临床路径，并凸显了实验室发展和临床医生教育的重要性。

对2025年关税变化及其对芽生菌病相关产品的供应链、采购决策和商业策略的实际影响进行评估

2025年的关税政策变更为参与芽生菌病相关诊断和治疗产品生产、进口和分销的相关人员带来了更多复杂性。某些医疗产品关税的提高可能会影响单位经济效益，并促使製造商和经销商重新评估筹资策略、区域生产基地和合约定价模式。对于经常跨境分销的诊断设备和试剂而言，关税导致的成本增加可能会导致医院和实验室的采购週期延长，因为需要重新评估其资金配置决策。

可操作的细分讯息，描述了产品、最终用户、分销管道和给药途径方面的差异，这些差异会推动产品的采用、采购和临床应用。

细分市场分析揭示了产品类型、最终用户、分销管道和给药途径的关键转折点，这些因素共同决定了市场动态和临床应用。基于产品类型的市场格局可分为诊断和治疗两大类。诊断类产品进一步细分为影像学检测、分子检测和血清学检测，而治疗类产品则分为Azole和Polyenes。Azole又进一步细分为Fluconazole和Itraconazole。这些产品层面的差异会影响临床工作流程、投资重点以及相关人员愿意接受的证据类型。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 照护现场分子诊断技术正日益应用于社区医疗机构，以促进芽生菌病的快速检测。
  • 增加对皮肤炎芽生菌（Blastomyces dermatitidis）的抗真菌药物研发管线的投资，该菌对传统治疗方法具有抗药性。
  • 扩大远端医疗主导的病患监测服务，以管理慢性芽生菌併发症
  • 州卫生部门扩大宣传活动，以提高地方性流行地区的早期诊断率
  • 利用重组抗原开发用于预防芽孢菌感染疾病的新型候选疫苗
  • 利用人工智慧整合影像分析工具，鑑别芽生菌病与其他类似肺部疾病。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的芽生菌病市场

  • 诊断试剂
    • 影像诊断
    • 分子检测
    • 血清学检测
  • 治疗药物
    • Azole
      • Fluconazole
      • Itraconazole
    • Polyenes

第九章 依最终用户分類的芽生菌病市场

  • 门诊护理设施
  • 诊断实验室
  • 医院

第十章 依分销通路分類的芽生菌病市场

  • 直接竞标
  • 批发商
  • 线上零售

第十一章 依给药途径分類的芽生菌病市场

  • 静脉注射
  • 口服
    • 胶囊
    • 口服液

第十二章 区域性芽生菌病市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 芽生菌病市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国芽生菌病市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Astellas Pharma Inc.
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Fresenius Kabi AG
    • Amphastar Pharmaceuticals, Inc.
Product Code: MRR-1A1A064C0289

The Blastomycosis Market is projected to grow by USD 212.24 million at a CAGR of 3.43% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 161.94 million
Estimated Year [2025] USD 167.57 million
Forecast Year [2032] USD 212.24 million
CAGR (%) 3.43%

A focused clinical and commercial introduction to blastomycosis emphasizing diagnostic hurdles, therapeutic pathways, and strategic imperatives for stakeholders

Blastomycosis remains an underrecognized fungal infection with outsized implications for clinical pathways, diagnostic workflow design, and therapeutic strategy. Although incidence is relatively localized in endemic regions, clinicians and health systems face significant diagnostic delays owing to nonspecific presentations and limitations in current testing modalities. Consequently, patient outcomes hinge on timely recognition and the availability of reliable diagnostic tools paired with effective antifungal regimens. From a commercial perspective, these clinical realities translate into distinct demand drivers for diagnostics innovation, improved molecular assays, and targeted therapeutics.

In addition, evolving awareness among frontline clinicians and public health authorities is beginning to reshape detection efforts, which in turn affects procurement cycles and formulary decisions. Diagnostic laboratories and hospitals must balance speed, sensitivity, and cost when selecting tests, while ambulatory care settings increasingly require accessible point-of-care solutions. Therapeutic selection is influenced by route of administration, patient comorbidities, and tolerability, with oral azoles and intravenous polyenes continuing to play established roles. Taken together, these dynamics create an environment where strategic investment in diagnostic accuracy and therapeutic optimization offers the greatest potential for clinical and commercial impact.

Emerging diagnostic innovations, therapeutic refinements, and supply chain adaptations reshaping clinical pathways and market opportunities in blastomycosis care

The landscape for blastomycosis is undergoing transformative shifts driven by technological advances, regulatory attention, and changing clinical practice patterns. Key innovations in molecular diagnostics are increasing the sensitivity and speed of detection, enabling earlier initiation of therapy. Simultaneously, refinements in serological assays and imaging interpretation frameworks are helping to reduce diagnostic uncertainty, which historically contributed to treatment delays and poorer outcomes. These diagnostic improvements are reshaping clinical pathways and elevating the importance of laboratory readiness and clinician education.

On the therapeutic front, stewardship considerations and evolving evidence on azole efficacy and safety are prompting more nuanced prescribing practices. The balance between oral and intravenous administration is influenced by patient acuity and care setting, while formulation improvements aim to enhance adherence and tolerability. Moreover, supply chain resilience and distribution channel optimization are becoming strategic priorities as stakeholders seek to ensure uninterrupted access to critical diagnostics and antifungals. Together, these trends are converging to create new opportunities for diagnostic manufacturers, pharmaceutical developers, and health systems to collaborate on integrated care models that reduce time-to-diagnosis and improve patient outcomes.

Assessment of 2025 tariff shifts and their practical implications for supply chains, procurement decisions, and commercial strategies impacting blastomycosis products

Tariff policy changes in 2025 have introduced an additional layer of complexity for stakeholders involved in the manufacture, importation, and distribution of diagnostics and therapeutics relevant to blastomycosis. Increased duties on certain medical goods can influence unit economics, prompting manufacturers and distributors to reassess sourcing strategies, regional production footprints, and contractual pricing models. For diagnostic equipment and reagents that cross borders frequently, tariff-induced cost inflation can translate into delayed procurement cycles for hospitals and laboratories as capital allocation decisions are revisited.

At the same time, therapeutics that depend on international raw materials or finished-good imports face potential margin pressure that may affect availability or lead to preferential stocking of domestically produced alternatives where feasible. In response, many firms are intensifying efforts to localize supply chains, diversify supplier bases, and negotiate longer-term purchasing agreements to stabilize costs. Payers and purchasing groups are likely to play a more prominent role in mediating access and cost-containment, and manufacturers will need to align commercial strategies with evolving reimbursement conversations and procurement tender practices to preserve market access amid tariff volatility.

Actionable segmentation intelligence describing product, end-user, distribution, and administration distinctions that drive adoption, procurement, and clinical use

Segmentation reveals critical inflection points across product types, end users, distribution channels, and administration routes that collectively define market dynamics and clinical adoption. Based on Product Type, the landscape spans Diagnostics and Therapeutics, with Diagnostics further differentiated by Imaging, Molecular Test, and Serological Test, and Therapeutics further divided into Azoles and Polyenes, with Azoles also split between Fluconazole and Itraconazole. These product-level distinctions influence clinical workflows, investment priorities, and the types of evidence stakeholders will accept for adoption.

Based on End User, demand patterns vary across Ambulatory Care Settings, Diagnostic Laboratories, and Hospitals, each with distinct purchasing cycles, volume requirements, and clinical priorities. Based on Distribution Channel, procurement and logistics differ when sourced via Direct Tender, Distributor, or Online Retail, affecting time-to-market and inventory management. Based on Route Of Administration, choices between Intravenous and Oral therapies shape inpatient versus outpatient treatment pathways, and the Oral category itself is further delineated into Capsules and Oral Solution, which have implications for adherence, dosing flexibility, and patient preference. Understanding these intersecting segmentation dimensions enables more precise targeting of clinical evidence generation, commercialization tactics, and supply chain design.

Geographic differentiation and regional strategies reflecting endemic patterns, healthcare capabilities, and regulatory environments that shape readiness and demand

Regional dynamics for blastomycosis reflect divergent epidemiology, healthcare infrastructure, and regulatory frameworks across major geographies. In the Americas, endemicity in certain regions drives concentrated clinical awareness, shaping demand for rapid diagnostics and effective antifungal options, while established hospital networks and laboratory systems create pathways for adoption of advanced molecular assays. In Europe, Middle East & Africa, variable surveillance capacity and differential access to diagnostics lead to heterogeneous needs; some markets prioritize affordable serological tests and capacity building, whereas others with advanced tertiary centers focus on cutting-edge molecular platforms and specialist therapeutics.

In the Asia-Pacific region, increasing investment in laboratory infrastructure, rising clinician familiarity with fungal infections, and expanding private-sector distribution networks are fueling opportunities for both diagnostics and therapeutics. Cross-regionally, regulatory harmonization, reimbursement mechanisms, and supply chain resilience emerge as common themes that influence how products are introduced and scaled. Consequently, tailored regional strategies that account for endemicity, healthcare delivery models, and payer environments are essential for successful market entry and sustained uptake.

Corporate strategies and partnership models revealing how diagnostics and therapeutics players differentiate through evidence generation, supply resilience, and clinical engagement

Company-level dynamics show a diverse ecosystem of diagnostic developers, pharmaceutical manufacturers, and specialized distributors engaged in addressing blastomycosis clinical needs. Leading stakeholders that prioritize investment in molecular diagnostic platforms are accelerating time-to-diagnosis through assay sensitivity and workflow integration, while others focus on improving serology performance and imaging interpretation support tools. On the therapeutics side, manufacturers with established antifungal portfolios concentrate on optimizing formulations, improving safety profiles, and supporting guideline-compliant use through medical education and stewardship programs.

Strategic partnerships between diagnostic companies and clinical networks are becoming more common, enabling validation studies and smoother adoption pathways. Similarly, collaborations between pharmaceutical firms and hospital systems can support real-world evidence generation and formulary inclusion. Competitive differentiation increasingly rests on the ability to demonstrate clinical utility, cost-effectiveness, and supply reliability. As a result, companies investing in clinician outreach, robust post-market surveillance, and flexible distribution arrangements are better positioned to capture clinical trust and long-term institutional relationships.

Pragmatic and integrated recommendations for leaders to accelerate diagnostic adoption, optimize therapeutic use, and secure resilient supply chains across markets

Industry leaders seeking to strengthen their position in blastomycosis care should prioritize a set of integrated actions that align clinical value with commercial viability. First, invest in robust diagnostic validation studies that demonstrate real-world sensitivity and specificity across representative patient cohorts, and pair that evidence with clinician-facing educational initiatives to reduce diagnostic delay. Second, optimize therapeutic offerings by considering patient-centric formulation advances and clear prescribing guidance that addresses safety and adherence concerns, while coordinating with stewardship programs to preserve therapeutic longevity.

Third, fortify supply chain resilience through supplier diversification, localized manufacturing where feasible, and flexible distribution agreements that mitigate tariff and logistic risks. Fourth, tailor market entry and scaling strategies to regional healthcare systems by aligning regulatory strategies, reimbursement dossiers, and local clinical champions. Fifth, engage in collaborative partnerships across diagnostics, therapeutics, and hospital networks to build integrated care pathways that shorten time-to-diagnosis and improve outcomes. Implementing these steps with clear KPIs and cross-functional governance will translate strategic intent into measurable impact.

Transparent multi-method research approach integrating primary clinical insights, authoritative literature synthesis, and rigorous validation to ensure actionable findings

This research adopts a multi-method approach combining primary and secondary evidence streams to construct a comprehensive view of blastomycosis clinical and commercial dynamics. Primary inputs include interviews with infectious disease clinicians, laboratory directors, hospital pharmacists, and distribution specialists to capture firsthand perspectives on diagnostic performance, therapeutic decision-making, procurement practices, and regional access barriers. These qualitative insights are triangulated with peer-reviewed clinical literature, regulatory guidance documents, and publicly available treatment guidelines to ensure clinical accuracy.

Analytical methods encompass segmentation analysis to delineate meaningful clinical and commercial cohorts, scenario planning to assess supply chain and tariff impacts, and company profiling to map strategic positioning and partnership activity. Data validation steps include cross-checking interview findings against published studies and regulatory sources, as well as reconciling discrepancies through follow-up conversations. The methodology emphasizes transparency, reproducibility, and relevance to decision-makers, and it is designed to support both strategic planning and operational implementation.

Strategic conclusion emphasizing the imperative for coordinated diagnostic innovation, therapeutic optimization, and resilient commercialization to improve patient outcomes

In conclusion, the evolving landscape of blastomycosis care presents clear opportunities for stakeholders who can align diagnostic innovation, therapeutic optimization, and resilient commercialization strategies. Improving diagnostic speed and accuracy remains the most direct lever to reduce clinical burden and improve patient outcomes, while therapeutic choices that prioritize safety, administration flexibility, and real-world support will enhance care continuity across settings. Regional differences underscore the need for bespoke approaches that reflect endemic patterns, healthcare infrastructure, and procurement norms.

Furthermore, recent tariff dynamics and supply chain pressures highlight the strategic importance of sourcing flexibility and distribution agility. Companies that invest in evidence generation, clinician engagement, and operational robustness will be best positioned to translate scientific advances into clinical adoption and institutional trust. Ultimately, coordinated action across manufacturers, health systems, and policymakers is required to close gaps in detection and treatment, and to ensure that patients receive timely, effective care regardless of geography.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of point-of-care molecular diagnostics to accelerate blastomycosis detection in regional clinics
  • 5.2. Rising investment in antifungal pipeline targeting Blastomyces dermatitidis resistant to conventional therapies
  • 5.3. Growth of telehealth-driven patient monitoring services for managing chronic blastomycosis complications
  • 5.4. Expansion of awareness campaigns by state health departments to improve early diagnosis rates in endemic regions
  • 5.5. Development of novel vaccine candidates utilizing recombinant antigens to prevent blastomycosis infections
  • 5.6. Integration of AI-powered imaging analysis tools to differentiate blastomycosis from similar pulmonary diseases

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blastomycosis Market, by Product Type

  • 8.1. Diagnostics
    • 8.1.1. Imaging
    • 8.1.2. Molecular Test
    • 8.1.3. Serological Test
  • 8.2. Therapeutics
    • 8.2.1. Azoles
      • 8.2.1.1. Fluconazole
      • 8.2.1.2. Itraconazole
    • 8.2.2. Polyenes

9. Blastomycosis Market, by End User

  • 9.1. Ambulatory Care Settings
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals

10. Blastomycosis Market, by Distribution Channel

  • 10.1. Direct Tender
  • 10.2. Distributor
  • 10.3. Online Retail

11. Blastomycosis Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
    • 11.2.1. Capsules
    • 11.2.2. Oral Solution

12. Blastomycosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blastomycosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blastomycosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Pfizer Inc.
    • 15.3.2. Merck & Co., Inc.
    • 15.3.3. Gilead Sciences, Inc.
    • 15.3.4. Johnson & Johnson
    • 15.3.5. Astellas Pharma Inc.
    • 15.3.6. Viatris Inc.
    • 15.3.7. Teva Pharmaceutical Industries Ltd.
    • 15.3.8. Sandoz International GmbH
    • 15.3.9. Fresenius Kabi AG
    • 15.3.10. Amphastar Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BLASTOMYCOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BLASTOMYCOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLASTOMYCOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLASTOMYCOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLASTOMYCOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 301. GCC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GCC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GCC BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. GCC BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. GCC BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 306. GCC BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 307. GCC BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 308. GCC BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 309. GCC BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 310. GCC BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 311. GCC BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. GCC BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. GCC BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. GCC BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. GCC BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. GCC BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 317. GCC BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 318. GCC BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 337. BRICS BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. BRICS BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. BRICS BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. BRICS BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. BRICS BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 342. BRICS BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 352. BRICS BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 353. BRICS BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 354. BRICS BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 355. G7 BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 356. G7 BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 357. G7 BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 358. G7 BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 359. G7 BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 360. G7 BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)

TA